Today: 13 June 2026

Shan Ahmed Khan

As a journalist focused on finance and the stock market, he delivers fast, reliable, and easy-to-understand coverage of market news.

Intuitive Machines (LUNR) stock slides after Stifel downgrade as NASA moon rover decision nears

Intuitive Machines (LUNR) stock slides after Stifel downgrade as NASA moon rover decision nears

Intuitive Machines shares fell 3.8% to $18.88 Friday after Stifel downgraded the stock to “hold,” citing uncertainty over a pending NASA rover contract. The stock swung between $17.82 and $19.73 on heavy volume. NASA’s Lunar Terrain Vehicle award remains undecided. Investors are also watching for U.S. inflation data on Jan. 13 and company earnings on March 19.
9 January 2026
··
Why Equity Residential stock is sliding today: BMO downgrade meets a $400 million asset sale

Why Equity Residential stock is sliding today: BMO downgrade meets a $400 million asset sale

Equity Residential shares fell 3.8% to $60.46 after BMO Capital downgraded the stock, citing softening rental markets in major coastal cities. The drop followed news of a $400 million sale of three properties to JRK Property Holdings. Other large apartment REITs also traded lower. Investors are watching for upcoming U.S. inflation data and Equity Residential’s earnings on Feb. 2.
9 January 2026
···
Valero (VLO) stock slides as Venezuela oil talks loom and an analyst trims a target

Valero (VLO) stock slides as Venezuela oil talks loom and an analyst trims a target

Valero shares dropped 3.2% to $185.16 Friday afternoon, underperforming other refiners as the White House met with oil firms, including Valero and Marathon, to discuss possible investment in Venezuela. Piper Sandler cut its Valero price target to $217. Oil prices rose amid global supply concerns. Investors await Valero’s Jan. 29 earnings report for margin and policy updates.
9 January 2026
·····
CRISPR Therapeutics stock slides after CFO share-sale filing; JPM conference next

CRISPR Therapeutics stock slides after CFO share-sale filing; JPM conference next

CRISPR Therapeutics shares fell 4.3% to $54.00 after a filing showed CFO Raju Prasad exercised and sold 29,700 shares under a preset trading plan. The move comes ahead of the company’s Jan. 12 slot at the J.P. Morgan Healthcare Conference and an expected mid-February earnings report. Gene-editing peers also traded lower. CASGEVY revenue and rollout remain key investor focus.
9 January 2026
·······
Costco Canada recall expands: Peace by Chocolate pistachio chocolates pulled over salmonella risk

Costco Canada recall expands: Peace by Chocolate pistachio chocolates pulled over salmonella risk

Costco Canada recalled certain Peace by Chocolate gift boxes sold online after a supplier warned of possible Salmonella in two pistachio chocolates. The recall affects products bought on Costco.ca between Sept. 7 and Dec. 3, with no reported illnesses as of Jan. 8. Canada’s pistachio recall list now covers over 330 products. The CFIA says its investigation is ongoing and more recalls may follow.
9 January 2026
·
Why Abercrombie & Fitch stock is sliding today despite a UBS target hike

Why Abercrombie & Fitch stock is sliding today despite a UBS target hike

Abercrombie & Fitch shares dropped 3.7% to $125.09 Friday after a weaker U.S. jobs report and mixed consumer sentiment data. UBS raised its price target on the stock to $160, citing expected 2026 earnings growth. Payrolls rose by 50,000 in December, with job losses in retail. Investors await the Fed’s Jan. 27-28 meeting and Abercrombie’s next results, expected in early March.
9 January 2026
·
HealthEquity stock slides after Goldman Sachs downgrade; HQY earnings watch shifts to March

HealthEquity stock slides after Goldman Sachs downgrade; HQY earnings watch shifts to March

HealthEquity shares dropped 2.9% to $95.64 Friday after Goldman Sachs downgraded the stock to sell and set an $89 target. The move followed HealthEquity’s raised fiscal 2026 revenue outlook and a report of $34.4 billion in HSA assets. KeyBanc maintained an Overweight rating and lifted its price target to $125. The stock fell as the S&P 500 and Nasdaq 100 rose.
9 January 2026
···
Nuvation Bio stock falls as UBS starts coverage; NUVB investors eye JPM conference next week

Nuvation Bio stock falls as UBS starts coverage; NUVB investors eye JPM conference next week

Nuvation Bio shares fell 4.7% to $8.05 Friday afternoon, underperforming biotech peers. UBS began coverage at Neutral with a $10 target, while RBC raised its target to $9 and reiterated Outperform. CEO David Hung is set to present at the J.P. Morgan Healthcare Conference on Jan. 13. Investors await early March results for updates on IBTROZI’s launch and pipeline spending.
9 January 2026
·
PVH stock slips as Supreme Court tariff decision hangs over retailers — what traders watch next

PVH stock slips as Supreme Court tariff decision hangs over retailers — what traders watch next

PVH Corp shares slid 4.4% to $65.32 Friday afternoon, underperforming the consumer discretionary sector, after the U.S. Supreme Court delayed a decision on Trump-era tariffs until Jan. 14. PVH has warned tariffs could cut 2025 earnings by $65 million. Interim CFO Melissa Stone reported holding 15,410 shares in a recent SEC filing. Investors are watching for any tariff policy changes that could affect costs.
9 January 2026
·
MakeMyTrip stock slides 4.5% in U.S. trade as investors turn to Jan. 22 earnings

MakeMyTrip stock slides 4.5% in U.S. trade as investors turn to Jan. 22 earnings

MakeMyTrip shares fell 4.5% to $78.78 in Friday afternoon trading, underperforming U.S.-listed travel peers. The stock hit a session high of $83.42 before sliding, with no new company updates ahead of its expected Jan. 22 earnings. Trading volume reached about 577,000 shares by mid-session. The drop puts MakeMyTrip near its lowest levels since early January.
9 January 2026
··
Lululemon stock sinks nearly 5% as Supreme Court tariff ruling slips, keeping retailers on edge

Lululemon stock sinks nearly 5% as Supreme Court tariff ruling slips, keeping retailers on edge

lululemon athletica shares fell 4.9% to $201.88 Friday after the U.S. Supreme Court delayed a key tariffs ruling. The company warned higher tariffs and loss of the “de minimis” exemption could cut 2025 gross profit by $240 million. Investors also weighed an upcoming CEO transition and a proxy fight from founder Chip Wilson. The court could rule next week.
9 January 2026
····
WD-40 stock slides 6% after Q1 profit falls; guidance held and Asia rebound in focus

WD-40 stock slides 6% after Q1 profit falls; guidance held and Asia rebound in focus

WD-40 shares dropped 5.6% to $192.13 after reporting a first-quarter profit decline and higher expenses, with the stock hitting a session low near $175. Net sales rose 1% to $154.4 million, but diluted EPS fell to $1.28 from $1.39. Management reaffirmed full-year guidance and blamed weak distributor markets for the profit slip. Investors await more detail at the Jan. 13 ICR Conference.
9 January 2026
··
Atour Lifestyle (ATAT) stock slides about 4% in U.S. trade as rate bets shift, CPI looms

Atour Lifestyle (ATAT) stock slides about 4% in U.S. trade as rate bets shift, CPI looms

Atour Lifestyle Holdings’ U.S. shares dropped 4.2% to $40.20 in early afternoon trading Friday, outpacing losses in other China travel stocks. The move followed weaker-than-expected U.S. payrolls data and uncertainty over Federal Reserve policy and tariffs. Trading volume reached about 894,000 shares. Investors now await the U.S. CPI report on Jan. 13.
9 January 2026
····
1 … 273 274 275 276 277 … 590

Stock Market Today

  • Caledonia Mining Reports High Grade Motapa Drilling Amid Depressed Shares
    June 13, 2026, 3:48 PM EDT. Caledonia Mining (NYSEAM:CMCL) announced significant high grade gold drilling results from its 2025 exploration at Motapa, Zimbabwe, revealing continuous mineralised zones near the Bilboes Gold Project. This proximity offers potential operational synergies and shared infrastructure, with a maiden resource estimate pending to clarify Motapa's role in Caledonia's production plans. Despite this, shares trade at $20.18, down 18.5% in the last month and 23.4% year-to-date, and currently about 53% below the $42.73 analyst target price. Investors should monitor the upcoming resource estimate and integration efforts between Motapa and Bilboes, noting execution risks in permitting and development remain. The stock is also estimated to trade nearly 24% below fair value, suggesting a discounted entry point amid mixed market sentiment.

Latest articles

KLA Jumps After 10-for-1 Stock Split; AI Chip Boom Lifts Hopes on Tools

KLA Jumps After 10-for-1 Stock Split; AI Chip Boom Lifts Hopes on Tools

13 June 2026
KLA soared 5.55% to $254.54 on its first split-adjusted day after a 10-for-1 stock split and analyst price target hikes tied to AI-driven chip equipment demand, but with the stock now above several split-adjusted targets, investors face heightened risk ahead of the fiscal Q4 report, which will be the next key catalyst for revenue, earnings, and AI-linked demand guidance.
Pfizer trades around $26 with dividend in focus, drug-price worries linger

Pfizer trades around $26 with dividend in focus, drug-price worries linger

13 June 2026
Pfizer closed at $26.21, up 0.15%, outperforming the Health Care Select Sector SPDR ETF despite new German drug-pricing pressures and a European legal setback; investors are focused on the 6.56% dividend yield, reaffirmed 2026 guidance, and pipeline progress in obesity and oncology as Q2 earnings on August 4 approach.
Go toTop